Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. - Chodak, G W; Vogelzang, N J; Caplan, R J; Soloway, M; Smith, J A (JAMA: Journal of the American Medical Association, 1991)